NEW YORK — Stratify Genomics, a maker of genetic-based cancer risk tests, said on Wednesday that it has raised $2.2 million in seed funding from undisclosed angel investors.
In late 2018, the San Diego-based company launched Prompt Prostate Genetic Score (PGS), a lab-developed test that incorporates genetic information from several prostate cancer-risk associated SNPs and population analyses to track a man's genetic predisposition to the disease.
Stratify said it will use the proceeds of the financing to support sales and partnership efforts around the test.
"We are excited for the commercial partnership opportunities that have emerged since launching Prompt PGS," Stratify President Martyn Gross said in a statement. "This funding will help fuel further adoption of our prostate cancer risk test so that we can get closer to our goal of nationwide risk screening and a significant reduction of metastatic prostate cancer in the US and abroad."